4 terminated. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 4 |
Follow Chromosome Disorders: new trials by email Literature Review of Chromosome Disorders trials Research Report on Chromosome Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD) ION269 - Alzheimer Disease, Down Syndrome | Phase 1 | Terminated | Ionis Pharmaceuticals, Inc. | 1 | 2024-12-20 | 2026-02-20 |
| Neuroimaging GABA Physiology in Fragile X Syndrome [18F]flumazenil - Fragile X Syndrome (FXS), Idiopathic Intellectual Developmental Disorder (IDD) | Phase 1 | Terminated | Stanford University | 17 | 2016-11-01 | 2021-01-28 |
| Initiating Transdermal Estradiol Therapy in Turner's Syndrome Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch - Turner's Syndrome | Phase 1 | Terminated | University of Chicago | 1 | 2009-04-01 | 2014-03-11 |
| Serum-Free Thymus Transplantation in DiGeorge Anomaly Serum Free Thymus Transplantation with Immunosuppression, Serum Free Thymus Transplantation without immunosuppression - DiGeorge Anomaly | Phase 1 | Terminated | Sumitomo Pharma Switzerland GmbH | 2 | 2008-04-01 | 2022-04-01 |
Alzheimer Disease (1) · DiGeorge Syndrome (1) · Down Syndrome (1) · Fragile X Syndrome (1) · Immunologic Deficiency Syndromes (1) · Intellectual Disability (1) · Thymic aplasia (1) · Turner Syndrome (1)
Congenital Abnormalities (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Abnormalities, Multiple (2) · Cardiovascular Abnormalities (2) · Cardiovascular Diseases (2) · Endocrine System Diseases (2) · Heart Defects, Congenital (2) · Heart Diseases (2) · Mental Disorders (2) · Nervous System Diseases (2) · Neurobehavioral Manifestations (2) · Neurologic Manifestations (2) · Sex Chromosome Disorders (2)
5-(2'-fluoroethyl)flumazenil (1) · Estradiol (1) · Human Growth Hormone (1) · Immunosuppression Therapy (1) · Transdermal Patch (1)
Ionis Pharmaceuticals, Inc. (1) · Stanford University (1) · Sumitomo Pharma Switzerland GmbH (1) · University of Chicago (1)
United States (3) · Spain (1)
Frederick T Chin, PhD (1) · M. Louise Markert, M.D., Ph.D (1) · Robert L. Rosenfield, MD (1)
2023 (1), K12HD043494 (1), R01AI047040 (1), R01AI054843 (1)